Connect your AI

CG Oncology CGON Retained Earnings

Retained Earnings at other companies

PfizerPFE

$117.24B-2.0%

Johnson & JohnsonJNJ

$169.16B+4.0%

Gilead SciencesGILD

$14.13B+29.3%

ImmunityBio, Inc.IBRX

-$4.36B-24.4%

Cogent Biosciences, Inc.COGT

-$1.29B-38.0%

Tango TherapeuticsTNGX

-$648.67M-19.8%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's retained earnings?: CG Oncology (CGON) reported retained earnings of -$439.18M in Q1 2026.
How has CG Oncology's retained earnings changed year-over-year?: CG Oncology's retained earnings decreased by 74.0% year-over-year, from -$252.43M to -$439.18M.
What is the long-term trend for CG Oncology's retained earnings?: Over 2 years (2023 to 2025), CG Oncology's retained earnings has grown at a 70.8% compound annual growth rate (CAGR), from -$129.94M to -$378.98M.
What does retained earnings mean?: Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.